<DOC>
	<DOC>NCT01669876</DOC>
	<brief_summary>To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on blood levels of amyloid beta (AÎ²), or impacts global or functional measures of Alzheimer's Disease (AD) in subjects with mild to moderate AD.</brief_summary>
	<brief_title>Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>At least 65 years old. Have a diagnosis of probable AD or a concurrent diagnosis of probable AD and possible or probable vascular dementia. Score 16 or more on the MiniMental State Examination (MMSE). Otherwise stable medical history and general health. Weigh between 45 kg and 120 kg inclusive. Have contraindications, allergy, or sensitivity to the study products or their components. Be currently taking any of the following medications: systemic (oral or injectable) glucocorticoids; interferonalpha; antiCD20 antibody (e.g., rituximab); or antiCTLA4 antibody (e.g., ipilimumab). Be a current smoker or smokeless tobacco user.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Dietary Supplements</keyword>
</DOC>